Latest Proteasome Stories
Compounds that kill dormant pathogen while sparing human cells could lead to new drugs.
Viruses have numerous tricks for dodging the immune system. In the September 7, 2009 issue of the Journal of Cell Biology, Stagg et al. reveal a key detail in one of these stratagems, identifying a protein that enables cytoÂ¬megalovirus to shut down an antiviral defense (online August 31).
The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.
Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes.
Gary Chiang, Ph.D., and colleagues at Burnham Institute for Medical Research (Burnham) have elucidated how the stability of the REDD1 protein is regulated. The REDD1 protein is a critical inhibitor of the mTOR signaling pathway
Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.
Findings Published in Nature Medicine Suggest Broad Implications for the Treatment of Inflammatory and Autoimmune Disorders SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- Proteolix, Inc.
Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc.
Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the appointment of John A.
- To give a box on the ear to.